Gamma-aminobutyric acid A receptor subunit alpha-3 (GABRA3)

Gamma‑aminobutyric acid A receptor subunit alpha‑3 is a protein encoded by the *GABRA3* gene in humans. It forms part of the pentameric structure of the gamma‑aminobutyric acid type A (GABA\(_A\)) receptors—major inhibitory neurotransmitter-gated chloride channels in the mammalian brain. The presence of different combinations of nineteen known GABA\(_A\) receptor subunits—including six types of alpha (\(\alpha1–6\)), three beta (\(\beta1–3\)), three gamma (\(\gamma1–3\)), among others—gives rise to a wide diversity of functional receptors with distinct pharmacological properties. The inclusion of an \(\alpha_3\) subunit confers unique physiological roles; it is involved primarily in mediating anxiolytic effects without causing significant sedation or motor impairment when targeted selectively. Subtype-specific ligands that preferentially modulate \(\alpha_3\)-containing receptors have shown promise as next-generation anxiolytics with reduced side effect profiles compared to traditional benzodiazepines. Structurally, each \(\alpha_3\) polypeptide features a long extracellular N-terminal domain containing a Cys-loop motif critical for ligand binding, four transmembrane domains forming part of an ion-conducting pore, and intracellular loops important for post-translational regulation such as phosphorylation. The mature pentameric complex typically assembles from two \(\alpha\), two \(\beta\), and one additional (\(\gamma/\delta/\epsilon/\pi/\rho)\)) subunits. Alterations in expression or function have been implicated in various CNS diseases including anxiety disorders, epilepsy/seizures, schizophrenia spectrum illnesses, and Down syndrome-related cognitive dysfunctions.[1][2][4][5]

Other names

GABA(A) receptor alpha 3 subunitGABA-A receptor subunit alpha-3GBRA3 proteinGamma-aminobutyric acid type A receptor subunit alpha 3[5][8]

Drugs targeting this molecule typically act via one or more of the following mechanisms: - Positive allosteric modulation at benzodiazepine binding site to enhance GABAergic inhibition[9] - Direct activation as selective agonists at the α3-containing pentameric complex[10] - Partial/inverse modulation depending on ligand selectivity for specific subunits